ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

ACRX AcelRX Pharmaceuticals Inc

0,86
0,00 (0,00%)
02 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
AcelRX Pharmaceuticals Inc ACRX NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,00 0,00% 0,86 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
0,86
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
29.4.202422:25EDGAR2Form ARS - Annual Report to Security Holders
29.4.202422:24EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
29.4.202422:23EDGAR2Form DEF 14A - Other definitive proxy statements
19.4.202422:37EDGAR2Form 8-K - Current report
21.3.202421:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.3.202421:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.3.202423:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.1.202415:17EDGAR2Form 8-K - Current report
09.1.202415:05PRNUSAcelRx Announces Rebranding With Name Change to Talphera,..
14.12.202314:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.12.202322:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.12.202322:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.12.202314:30PRNUSAcelRx Pharmaceuticals Announces Publication of Study..
22.11.202322:38EDGAR2Form S-3 - Registration statement under Securities Act of..
22.11.202322:34EDGAR2Form S-8 - Securities to be offered to employees in employee..
14.11.202312:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08.11.202322:14EDGAR2Form 8-K - Current report
08.11.202322:05PRNUSAcelRx Reports Third Quarter 2023 Financial Results and..
07.11.202322:05PRNUSAcelRx to Host KOL Panel Discussion on Current Anticoagulant..
26.10.202322:30PRNUSAcelRx to Host Third Quarter 2023 Financial Results Call and..
20.10.202322:30EDGAR2Form 8-K - Current report
10.10.202322:17EDGAR2Form 8-K - Current report
05.10.202322:45EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
05.10.202322:30EDGAR2Form 8-K - Current report
03.10.202314:30PRNUSAcelRx Receives IDE Approval for Niyad and Advances to a..
22.9.202323:18EDGAR2Form 8-K - Current report
12.9.202301:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.9.202314:30PRNUSAcelRx Pharmaceuticals to Participate in the H.C. Wainwright..
28.8.202312:35EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
28.8.202312:34EDGAR2Form DEF 14A - Other definitive proxy statements
25.8.202322:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25.8.202318:45EDGAR2Form 144 - Report of proposed sale of securities
24.8.202322:23EDGAR2Form 144 - Report of proposed sale of securities
10.8.202323:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10.8.202322:10EDGAR2Form 8-K - Current report
10.8.202322:05PRNUSAcelRx Reports Second Quarter 2023 Financial Results and..
09.8.202323:29EDGAR2Form 424B7 - Prospectus [Rule 424(b)(7)]
02.8.202312:06EDGAR2Form S-3 - Registration statement under Securities Act of..
27.7.202322:05PRNUSAcelRx to Host Second Quarter 2023 Financial Results Call..
21.7.202314:15EDGAR2Form 8-K - Current report
21.7.202314:00PRNUSAcelRx Pharmaceuticals Announces Closing of Previously..
18.7.202314:00PRNUSAcelRx Pharmaceuticals Announces $10 Million Private..
10.5.202322:05PRNUSAcelRx Pharmaceuticals Reports First Quarter 2023 Financial..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock